CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates
Bausch + Lomb's LuxLife IOL receives CE Mark approval in Europe